SETTLEMENT AGREEMENT AND RELEASE

CA Citizen Protection Group, LLC ("CCPG") and Compass Health Brands Corp. ("COMPASS") enter into this Settlement Agreement and Release (this "Agreement"). This Agreement is effective on the date on which it is fully executed by all Parties ("Effective Date"). CCPG and COMPASS are referred to individually as a "Party" and collectively as the "Parties." The Parties agree as follows:

1. The "**Matter**" arises out of a Sixty-Day Notice of Intent to Sue for Violations of the Safe Drinking Water and Toxic Enforcement Act of 1986, codified under California Health & Safety Code ("**HSC**") sections 25249.5, *et seq.* (referred to as "**Proposition 65**"), that CCPG served on COMPASS, Apex Medical Corporation d/b/a in California as Carex Health Brands, and Rite Aid Corporation, dated May 27, 2022 (filed as AG No. 2022-01093) (the "**Notice**") with respect to a product sold by COMPASS and the other noticed parties. The Notice claims that Proposition 65 warnings are required for alleged Diisononyl Phthalate ("**DINP**") exposures to a product tested by CCPG. The following product manufactured, distributed and/or sold by COMPASS is referred to as the "**Covered Product**" under this Agreement:

• Apex Carex Healthcare Products Adjustable Folding Cane (clear plastic storage case)

2. The Parties enter into this Agreement in order to fully resolve all claims, demands, and allegations regarding the Matter and for the purpose of avoiding prolonged litigation. Nothing in this Agreement shall be construed as an admission of the Parties of any fact, issue of law, or violation of law, nor shall compliance with this Agreement constitute or be construed as an admission by the Parties of any fact, issue of law, or violation of law including but not limited to Proposition 65. Nothing in this Agreement or any document referred to shall be construed as giving rise to any presumption or inference of admission or concession by the Parties as to any fault, wrongdoing, or liability. This <u>Section 2</u> shall not diminish or otherwise affect the obligations, responsibilities, and duties of the Parties under this Agreement.

3. <u>DINP Standards; Warnings.</u>

3.1 On and after the date that is ninety (90) days after the Effective Date, COMPASS shall not sell in the State of California a Covered Product which does not qualify as a Reformulated Covered Product under <u>Section 3.3</u>, unless such Covered Product complies with the warning requirements of <u>Section 3.2</u>.

3.2 On and after ninety (90) days after the Effective Date, COMPASS shall provide on the Covered Products sold in California (to the extent it does not constitute a Reformulated Covered Product) a warning that complies with the requirements of <u>Sections 3.2.1, 3.2.2</u>, or <u>3.2.3</u>. The warning shall be displayed on the packaging of the Covered Product with such conspicuousness, as compared with other words, statements, or designs so as to render it likely to be read and understood by an ordinary individual purchasing or using the Covered Product.

Respecting the warnings defined in <u>Sections 3.2.1</u> or <u>3.2.2</u>, the warning must be in a type size no smaller than the largest type size used for other consumer information on the product. In no case shall the warning appear in a type size smaller than 6-point type.

3.2.1 <u>Option 1.</u>

For the Covered Product, the warning may state:

WARNING: This product can expose you to chemicals, including Diisononyl Phthalate (DINP), which are known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

3.2.2 <u>Option 2.</u>

For the Covered Product, the warning may state:

WARNING: Cancer – www.P65Warnings.ca.gov.

The pictogram specified in <u>Section 3.2.1 and 3.2.2</u> shall be in yellow with a black exclamation mark; *provided however*, the pictogram may be in white instead of yellow if the Covered Product label does not contain the color commonly referred to as yellow.

3.2.3 <u>Option 3.</u>

The Covered Product may also be affixed with any warning authorized by any Proposition 65 law or regulation in effect on or after the Effective Date.

3.3 <u>Reformulated Covered Product</u>. A Reformulated Covered Product is one for which the concentration of DINP is less than 0.1% by weight (1,000 parts per million (ppm)) as tested by an approved laboratory and methods in compliance with <u>Section 3.4</u> below. For a Covered Product that contains (any part of the product/packaging) more than 0.1% by weight (1,000 ppm) DINP, COMPASS shall provide the warnings set forth in <u>Section 3.2</u>.

3.4. Formula, Testing and Quality Control Methodology.

3.4.1 For purposes of this Agreement, exposure levels shall be measured in parts per million (milligrams/kilogram or mg/kg) by generally accepted scientific standards. The testing requirements do not apply to any Covered Product for which COMPASS has provided a warning as specified in <u>Section 3.2</u>.

3.4.2 COMPASS shall not be required to engage in testing pursuant to this Agreement unless COMPASS sells into California the Covered Product without a warning. All testing pursuant to this Agreement shall be performed using a laboratory method that complies with any United States Environmental Protection Agency ("USEPA") or California Environmental Protection Agency ("CAEPA") approved testing method.

3.4.3 Unless warnings are affixed consistent with the requirements of <u>Section 3.2</u>, all testing pursuant to this Agreement shall be performed by an independent third-party laboratory approved by, accredited by, or registered with the CAEPA or USEPA. Testing shall be performed prior to COMPASS's "first sale" in California of the Covered Product ordered for production after the Effective Date, and testing shall continue thereafter at least once per year for three (3) consecutive years after the Effective Date (the "**Testing Period**"), after which time, no further testing shall be required under this Agreement, unless, after the Testing Period, COMPASS

changes suppliers for the Covered Product, then COMPASS shall test the Covered Product at least once after such change is made.

3.5 COMPASS and the "Releasees" (as defined in <u>Section 5.1</u> below) shall have no obligation or liability with respect to Covered Product that is sold or distributed in California after the date of this Agreement and the Notice, except as otherwise set forth in this Agreement.

4. COMPASS shall pay the total settlement amount of Eighteen Thousand Dollars and zero Cents (\$18,000.00) (the "Settlement Amount") within ten (10) days of the Effective Date. COMPASS shall pay the Settlement Amount payment by wire transfer (via account wire instructions provided by CCPG's counsel upon request), or check made payable to "*Khansari Law Corporation – Client Trust Account*" and sent via overnight with tracking (FedEx, UPS, or Express mail) to the mailing address below on behalf of CCPG:

Khansari Law Corporation 16133 Ventura Blvd., Suite 1200 Encino, CA 91436

CCPG shall be solely responsible for allocating the payment pursuant to <u>Sections 4.1</u> and <u>4.2</u>. As a condition to COMPASS's payment obligations arising under this Agreement, CCPG shall supply COMPASS with a completed W9 form on behalf of itself or its counsel, as applicable. The Settlement Amount shall be allocated as follows:

4.1. <u>\$500.00</u> shall be considered a "civil penalty", of which CCPG shall remit seventyfive percent (75%) to the "Safe Drinking Water and Toxic Enforcement Fund" managed by the State of California's Office of Environmental Health Hazard Assessment. The twenty-five percent (25%) balance shall be remitted to CCPG.

4.2 \$17,500.00 shall be considered reimbursement of CCPG's attorneys' fees and costs related to the Matter.

4.3 Except as expressly set forth in <u>Section 4</u>, the Parties shall bear their own costs, expenses, and attorneys' fees related to this Matter.

5. <u>Binding Effect; Claims Covered and Released.</u>

5.1. CCPG, on behalf of itself and its respective owners, principals, shareholders, officers, directors, employees, agents, parents, subsidiaries, successors, assigns, and legal representatives (collectively referred to as "CCPG Releasors") fully releases and waives any right to participate (directly or indirectly) in any litigation against (a) COMPASS, and its respective equity owners, parents, subsidiaries, affiliates, sister and related companies, (b) its upstream suppliers and all downstream entities in the stream of commerce including but not limited to distributors, wholesalers, customers, retailers, franchisees, cooperative members, and licensees (including specifically, and without limitation, Apex Medical Corporation d/b/a in California as Carex Health Brands, and Rite Aid Corporation, and their parent entities, subsidiaries and affiliate companies, as applicable)(the entities identified in this subsection (b) are collectively referred to as "Downstream Releasees"), and (c) the employees, shareholders, officers, directors, members, managers, equity owners, insurers, attorneys, predecessors, successors, and

assigns of any of the entities identified in subsections (a) and (b), above (the entities identified in subsections (a), (b) and (c), above, are collectively referred to as "**Releasees**") from all claims, actions, suits, demands, liabilities, damages, penalties, fees (including but not limited to attorneys' fees, investigator fees, and expert fees), costs, and expenses (collectively referred to as "**Claims**") that were asserted, or that could have been asserted, for any alleged violations of Proposition 65, or any other alleged violation of statutory or common law, arising from alleged exposures to DINP in the Covered Product.

5.2. It is possible that other claims not known to the Parties arising out of the facts alleged in the Notice and relating to the Covered Product will develop or be discovered. CCPG on behalf of itself and the CCPG Releasors, acknowledges that this Agreement is expressly intended to cover and include all such claims, including all rights of action therefore, and further acknowledges that the Claims released in this <u>Section 5</u> may include unknown claims, and nevertheless waives California Civil Code section 1542 as to any such unknown claims. California Civil Code section 1542 reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

CCPG acknowledges and understands the significance and consequences of this specific waiver of California Civil Code Section 1542.

5.3. The Parties agree that compliance with the terms of this Agreement shall constitute compliance by any Release with Proposition 65 regarding alleged exposures to DINP in the Covered Product.

5.4 It is the Parties' position that the commitments they have agreed to herein, and actions taken and to be taken by COMPASS under this Agreement, confer a significant benefit to the general public, as set forth in California Civil Procedure Code section 1021.5 and Cal. Admin. Code Title 11, section 3201. As such, to the extent any other private party initiates an action alleging a violation of Proposition 65 with respect to COMPASS or any Releasee's failure to provide a warning concerning exposures to DINP with respect to the Covered Product they have respectively manufactured, distributed, sold, licensed, or offered for sale in California, or will manufacture, distribute, sell, or offer for sale in California; such private party action would not confer a significant benefit on the general public as to the Covered Product addressed in this Agreement, provided that COMPASS is in compliance with this Agreement. This <u>subsection 5.4</u> does not constitute a release by CCPG under this Agreement.

6. <u>Resolution of Disputes</u>.

6.1 If CCPG alleges that COMPASS has failed to comply with this Agreement, prior to filing an action or motion relating to enforcement, CCPG shall first provide COMPASS thirty (30) days' advance written notice of the alleged violation(s). CCPG shall provide testing results, lot numbers, photographs of the Covered Product, and purchase receipts for the Covered Product at issue in the alleged violation, as applicable. The Parties shall meet and confer during such thirty (30) day period in an effort to reach agreement on an appropriate cure for the alleged violation without the need for litigation.

6.2 Notwithstanding the provisions of <u>Section 3</u>, CCPG may not issue any notice under <u>Section 6.1</u> if the packaging of a Covered Product is marked or labeled with the statement "Not for Sale in California" or substantially similar language, such statement is prominently placed upon such Covered Product's label or other labeling as compared with other words or statements on the label or labeling as to render it likely to be read and understood by an ordinary individual under customary conditions of purchase or use. If COMPASS marks or labels the Covered Product with such a statement, COMPASS shall additionally notify its customers/distributors by letter that the Covered Product shall not be sold in California.

6.3 In the event any litigation, arbitration, mediation, or other proceeding is initiated by any party to enforce this Agreement, the prevailing party shall be entitled to recover from the non-prevailing Party all costs, expenses, reasonable attorneys' fees, and expert witness fees, relating to or arising out of (i) such proceeding, and (ii) any post judgment or post-award proceeding including without limitation to enforce any judgment or award resulting from any such proceeding.

7. This Agreement contains the entire agreement between the Parties with regard to settlement of this Matter, and supersedes all prior or contemporaneous agreements or understandings, written or oral, with regard to the matters set forth in this Agreement. This Agreement may be amended or modified in whole or in part at any time only by an agreement in writing executed by the Parties. Notwithstanding the foregoing, COMPASS shall be entitled, at its option, to modify any warning that it provides under <u>Section 3.2</u> to conform with any change in the Proposition 65 warning regulations currently set forth in Title 27 of the California Code of Regulations that may be adopted after the Effective Date. CCPG shall cause this Agreement to be reported to the State of California Attorney General as required and applicable under Proposition 65 statutes, including specifically HSC § 25249.7.

8. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective owners, principals, shareholders, members, managers, officers, directors, employees, agents, successors, assigns and Releasees.

9. No inference, assumption or presumption shall be drawn, and no provision of this Agreement shall be construed against any of the Parties, based upon the fact that one of the Parties and/or one of the Parties' attorneys prepared and/or drafted all or any portion of this Agreement. It is conclusively presumed that the Parties participated equally in the preparation and drafting of this Agreement.

10. This Agreement shall be deemed to have been entered into in the State of California and governed and interpreted by the laws of the State of California, regardless of the place of incorporation, place of business, domicile of any of the Parties or physical locations of the individuals executing this Agreement at the time of execution.

11. The Parties acknowledge that they have a right to consult an attorney and they have consulted their attorneys with respect to the terms and conditions of this Agreement or by signing this Agreement hereby acknowledge they have made the decision not to consult with an attorney

in this Matter. The Parties further acknowledge that they fully understand this Agreement and the effect of signing and executing this Agreement.

12. Any legal action to enforce this Agreement or related to this Matter shall be brought in either the County of Alameda or the County of Los Angeles, of the State of California.

13. This Agreement may be signed in counterparts, and each counterpart, as well as any facsimile, e-mail (.pdf), copy of this Agreement, or any other counterpart, shall be deemed to be an original.

14. All notices required to be given to either Party under this Agreement shall be in writing and sent to the following recipients by (a) first-class mail or (b) overnight delivery, with a courtesy copy via email, as indicated below.

For <u>CCPG</u>:

CA Citizen Protection Group, LLC c/o Khansari Law Corporation 16133 Ventura Blvd., Suite 1200 Encino, California 91436 Fax: (818) 650-6445 Tel.: (818) 650-6444 Email: andre@khansarilaw.com

For <u>COMPASS</u>:

c/o Chris M. Amantea, Esq. Law Offices of Chris M. Amantea 7590 Fay Ave,, Suite 520 La Jolla, CA 92037 Tel,: (858) 352-6676 Email: camantea@CA-Envirolaw.com

15. Each of the individuals who executes this Agreement represents and warrants he/she has the authority to execute this document and bind the respective Parties to the terms and conditions of this Agreement, and has read, understood, and agreed to all the terms and conditions in this Agreement.

[Signatures Appear on the Following Pages]

DATED: April 15, 2023

CA CITIZEN PROTECTION GROUP, LLC

-	-101	
By:	Tal Ohana	
~ .	, and Chanta	

Name: Tal Ohana

Title: Manager

DATED: April<u>17</u>, 2023

11

COMPASS HEALTH BRANDS CORP.

By: Name: Title: